Loading
HI
Humanigen, Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Chappell Dale, was filed 20 May 2022.
Humanigen, Inc: what insiders have been doing
Humanigen, Inc, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). The past year has been quiet: not a single insider filing for Humanigen, Inc. The previous disclosure was published on 20 October 2023.
Our records for Humanigen, Inc go back to 2016, with 18 purchases and 127 sales on the open market in total.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
194
Thresholds
n/a
Buy Volume
€14M
18 ops. · all time
Sell Volume
€2B
127 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$2.2M
Net income-US$60.9M-2829.2% margin
Last declaration on 20 October 2023
Declarations194 total
75,887 shares@ US$0.0110.0% of flowCommon Stock, $0.001 par valueSEC:0001013594-23-000819:1
276,210 shares@ US$0.0110.0% of flowCommon Stock, $0.001 par valueSEC:0001013594-23-000819:2
34,253 shares@ US$0.0110.0% of flowCommon Stock, $0.001 par valueSEC:0001013594-23-000819:0
34,740 shares@ US$1.9620.1% of flowCommon Stock, $0.001 par valueSEC:0001013594-22-000446:1
Canonical exit: 16 Aug 2022 (T+90)
121,590 shares@ US$1.9620.3% of flowCommon Stock, $0.001 par valueSEC:0001013594-22-000446:2
Canonical exit: 16 Aug 2022 (T+90)
32,381 shares@ US$2.1860.1% of flowCommon Stock, $0.001 par valueSEC:0001013594-22-000446:3
Canonical exit: 17 Aug 2022 (T+90)
64,762 shares@ US$2.1860.2% of flowCommon Stock, $0.001 par valueSEC:0001013594-22-000446:4
Canonical exit: 17 Aug 2022 (T+90)
226,665 shares@ US$2.1860.7% of flowCommon Stock, $0.001 par valueSEC:0001013594-22-000446:5
Canonical exit: 17 Aug 2022 (T+90)
54,549 shares@ US$2.2280.2% of flowCommon Stock, $0.001 par valueSEC:0001013594-22-000446:6
Canonical exit: 18 Aug 2022 (T+90)
109,098 shares@ US$2.2280.4% of flowCommon Stock, $0.001 par valueSEC:0001013594-22-000446:7
Canonical exit: 18 Aug 2022 (T+90)
381,841 shares@ US$2.2281.2% of flowCommon Stock, $0.001 par valueSEC:0001013594-22-000446:8
Canonical exit: 18 Aug 2022 (T+90)
17,370 shares@ US$1.9622.0% of flowCommon Stock, $0.001 par valueSEC:0001013594-22-000446:0
Canonical exit: 16 Aug 2022 (T+90)
700,000 shares@ US$3.002.9% of flowCommon Stock, $0.001 par valueSEC:0001013594-22-000291:2
Canonical exit: 9 Jun 2022 (T+90)
200,000 shares@ US$3.000.8% of flowCommon Stock, $0.001 par valueSEC:0001013594-22-000291:1
Canonical exit: 9 Jun 2022 (T+90)
100,000 shares@ US$3.0016.7% of flowCommon Stock, $0.001 par valueSEC:0001013594-22-000291:0
Canonical exit: 9 Jun 2022 (T+90)
5,000 shares@ US$2.7843.9% of flowCommon StockSEC:0001214659-22-003919:1
Canonical exit: 7 Jun 2022 (T+90)
7,000 shares@ US$2.53100.0% of flowCommon StockSEC:0001214659-22-003919:0
Canonical exit: 6 Jun 2022 (T+90)
40,000 shares@ US$2.34100.0% of flowCommon StockSEC:0001214659-22-003623:0
Canonical exit: 31 May 2022 (T+90)
12,500 shares@ US$2.3218.3% of flowCommon StockSEC:0001214659-22-003622:0
Canonical exit: 31 May 2022 (T+90)
21,929 shares@ US$17.07430.5% of flowCommon Stock, $0.001 par valueSEC:0001013594-21-000672:2
11,510 shares@ US$17.15980.3% of flowCommon Stock, $0.001 par valueSEC:0001013594-21-000672:3
79,494 shares@ US$17.07431.9% of flowCommon Stock, $0.001 par valueSEC:0001013594-21-000672:4
41,725 shares@ US$17.15981.0% of flowCommon Stock, $0.001 par valueSEC:0001013594-21-000672:5
4,316 shares@ US$17.15980.1% of flowCommon Stock, $0.001 par valueSEC:0001013594-21-000672:1
8,224 shares@ US$17.07437.3% of flowCommon Stock, $0.001 par valueSEC:0001013594-21-000672:0
25 of 194 declarations
About Humanigen, Inc
Humanigen, Inc. (ticker: HGEN) is a U.S.-based biopharmaceutical company listed on the NASDAQ market in the United States. The company has historically positioned itself around innovative immunology and rare-disease programs rather than as a fully integrated commercial pharmaceutical group. Its U.S. headquarters is in Short Hills, New Jersey, with an operational footprint that also includes California, plus entities in Europe, the United Kingdom, and Australia. ([humanigen.com](https://humanigen.com/subsidiaries?utm_source=openai))
From a business-model perspective, Humanigen has been built around a pipeline of Humaneered monoclonal antibodies. The most frequently referenced programs in company materials and SEC filings include lenzilumab, ifabotuzumab, and HGEN005. In its SEC disclosures, the company has described lenzilumab as its lead asset, centered on the GM-CSF pathway and explored across inflammatory and hematologic indications, while ifabotuzumab and HGEN005 remain earlier-stage or more exploratory programs. Humanigen also disclosed that it changed its legal name in 2017, reflecting a strategic rebranding around this pipeline. ([humanigen.com](https://humanigen.com/our-programs/hgen005?utm_source=openai))
Read moreShow less
For French, Belgian, and Swiss investors, Humanigen should be viewed as a small-/micro-cap biotech with a high development-risk profile, limited commercial visibility, and heavy dependence on clinical outcomes, portfolio decisions, and financing capacity. Its competitive position is driven less by recurring revenues and more by the scientific and therapeutic potential of its assets, especially where GM-CSF biology may create differentiated treatment opportunities. The company has also emphasized a more capital-efficient, accelerated development model, which can be attractive in biotech but also increases execution risk. ([humanigen.com](https://humanigen.com/investors?utm_source=openai))
Recent public milestones have mainly centered on a strategic realignment of pipeline and resources announced in 2022 to focus on key clinical milestones. Earlier communications also highlighted manufacturing arrangements related to lenzilumab, including preparations for potential commercialization outside the United States, although those initiatives should be read in the context of a company that remains primarily clinical-stage. For investors tracking insider activity and SEC Form 4 filings, the key issue is therefore not scale today, but whether management can preserve cash, advance the core asset base, and maintain optionality in a highly competitive biotech environment. ([ir.humanigen.com](https://ir.humanigen.com/Korean/news/news-details/2021/Humanigen-and-Chime-Biologics-Enter-Into-Manufacturing-Agreement-for-COVID-19-Therapeutic-Candidate-Lenzilumab-/default.aspx?utm_source=openai))
